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Objectives/Hypothesis: Human papillomavirus-16 (HPV-16)–associated carcinoma of the oropharynx has a favorable
prognosis. Such patients have elevated CD8þ T-lymphocyte levels that correlate with response to chemotherapy and survival.
Tumor-infiltrating lymphocyte (TIL) subpopulations were assessed in pretreatment biopsies from a prospective patient cohort
to determine if TIL subsets differed by HPV status, clinical factors, or patient outcome or correlated with peripheral blood T-
cell levels.
Study Design: Retrospective immunological correlative study of patients entered in a prospective Phase 2 clinical trial.
Methods: Measured were CD8, CD4, CD68, and Treg (FoxP3) lymphocytes by immunohistochemistry in a tissue microar-
ray created from patients (n ¼ 46) with advanced oropharyngeal cancer. Correlations with peripheral blood levels, HPV sta-
tus, expression of epidermal growth factor receptor (EGFR), clinical tumor, and patient characteristics and outcome were
determined. Median follow-up was 6.6 years.
Results: HPV-16–positive patients had improved survival (P ¼ .016). Degree of T-cell infiltration did not differ by HPV
status but was significantly related to disease-specific survival (DSS) and overall survival (OS). Even after adjusting for HPV
status, we found that CD8, FoxP3, and total T cells were significantly associated with DSS (P ¼ .0236, P ¼ .0040, and P ¼
.0197, respectively) and OS (P ¼ .0137, P ¼ .0158, and P ¼ .0115, respectively). Less T-cell infiltration (P ¼ .0130) and CD4
cells in particular (P ¼ .0792) were associated with higher EGFR expression.
Conclusions: Improved outcomes are associated with increased TILs independent of HPV status and suggest the local
immune response may be more related to factors such as tumor size, EGFR expression, or performance status than HPV sta-
tus. Further study of larger numbers of patients and infiltrates combined with functional analysis of individual subsets may
be necessary to detect significant differences in local immunity in HPV-16–related cancers.
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INTRODUCTION
It is unclear why patients with human papillomavi-
rus-16 (HPV-16)–associated oropharyngeal cancer have a
more favorable prognosis than patients with HPV-16–
negative cancers.1–3 Patients with HPV-16–associated
cancers often are younger, frequently have large, cystic,
regional metastases, and often are nonsmokers.4–6 The
better prognosis of such patients is likely due to differen-
ces in tumor biology and differing oncogenesis but may
also reflect the role the host immune system and tumor
microenvironment play in cancer homeostasis.7,8
To better characterize potential differences in host
cellular immune reactivity among patients with HPV-
16–positive or negative cancers, we undertook a system-
atic analysis of T-lymphocyte subpopulations in the
peripheral blood and the tumor microenvironment in a
cohort of patients with advanced oropharyngeal cancer
who were entered in a prospective phase II clinical trial
of induction chemotherapy followed by concurrent che-
moradiation.9 We previously identified significantly
higher pretreatment levels of CD8-positive T lympho-
cytes in the peripheral blood of HPV-16 positive patients
that correlated with improved survival.10 Higher CD8
levels were also associated with tumor response to
induction chemotherapy. Others have noted low CD8 cell
infiltrates associated with poor cause-specific survival in
laryngeal cancer11 and higher T-cell infiltrates in
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patients with HPV-positive cancers that were associated
with improved survival only in patients with HPV-nega-
tive tumors.12 The current investigation extends these
findings to an examination of the characteristics of the
T-cell subpopulations infiltrating primary oropharyngeal
cancers by immunohistologic assessment of select T-cell
subpopulations in a tissue microarray (TMA) created
from pretreatment biopsies.
MATERIALS AND METHODS
Patient Population
Of 66 patients entered in the prospective clinical trial,
adequate tissue for creation of a TMA was available for 50
patients, and adequate tissue for immunohistologic analysis of
T-cell infiltrates on the microarray was present for 46 patients.
There were 36 male and 10 female patients. Mean age was 57
years (range, 39–77 years). A total of nine patients were stage
III and 37 were stage IV. A total of 15 patients were T1,2; 17
were T3; and 14 were T4. Only seven patients were N0; 10
were N1; 24 were N2; and five were N3. All patients had previ-
ously untreated, potentially resectable cancers. Eleven patients
were never smokers, 18 were past smokers having quit more
than a year before diagnosis, and 17 were current smokers.
Karnofsky performance status was 100 in 34 patients, 90 in
eight patients, and 80 in four patients. Site of primary tumor
was base of tongue in 27 and tonsil in 19 patients. Adequate
DNA for HPV testing was available for 38 of these cases. A total
of 25 patients had HPV-16–positive cancers, and 13 were nega-
tive for HPV-16 by highly sensitive and specific quantitative
method (Sensigen, Ann Arbor, MI) using combined real-time
competitive polymerase chain reaction and matrix-assisted laser
desorption ionization-time-of-flight mass spectroscopy testing.13
Clinical Treatment, Response to Chemotherapy,
and Survival
Patients received induction chemotherapy consisting of
one cycle of cisplatin (100 mg/m2/day for 1 day) and 5-fluoroura-
cil (1,000 mg/m2/day for 5 days). Carboplatin (area under the
curve) was used in place of cisplatin in patients with renal
insufficiency or hearing loss. Response to the initial chemother-
apy was evaluated by surface measurements at direct
laryngoscopy, supplemented by radiographic imaging (computed
tomography or magnetic resonance imaging) for deeply infiltra-
tive tumors. Patients who demonstrated at least a 50% tumor
reduction of the primary tumor were considered responders and
underwent definitive concurrent chemotherapy (cisplatin 100
mg/m2 days 1, 22, 43) and radiation therapy (70 Gy; daily 2 Gy
fractions  7 weeks). Following radiation, two cycles of adju-
vant paclitaxel (175 mg/m2) every 21 days was administered to
complete responders. Nonresponders to induction chemotherapy
received salvage surgery and radiation. A total of 39 patients
responded to induction chemotherapy and 36 were still consid-
ered responders 3 months after completion of concurrent
chemotherapy and radiation. One patient was nonevaluable for
induction response. Median follow-up of the patient cohort is
6.6 years. A total of 26 patients remained alive (56%), 15 died
of their cancer, and five died of other causes.
Immunohistology
Pretreatment biopsies were retrieved from 50 of 66
patients for construction of a TMA. Pathology blocks were not
available from 15 patients who had outside biopsies. Briefly,
TMA slides created from biopsy specimens from the patients in
this trial were deparaffinized, rehydrated, and peroxidase
quenched (Dako Cytomation, Glostrup, Denmark). For antigen
retrieval, slides were incubated with pepsin (epidermal growth
factor receptor [EGFR]; 10 minutes at 37C) or with citrate
buffer (p16 and p53; 30 minutes at 92C) and were blocked with
horse serum (30 minutes at 25C). Primary antibody, EGFR/
31G7 (Zymed Laboratories, South San Francisco, CA), p16/
16P04, and p53/DO1 (Lab-Vision, Fremont CA) were added for
1 hour and were probed with avidin/biotin peroxidase (ABC Kit;
Vector Laboratories, Burlingame, CA). Antibody binding was
scored by a pathologist who was blinded to the clinical outcome
using a continuous scale (i.e., 10%, 30%, 90%, etc.) for the pro-
portion of EGFR-positive tumor cells in each core. For p16 and
p53, a scale of 1 to 4 was used for tumor staining: 1 was less
than 5%; 2 was 5% to 20%; 3 was 21% to 50%; and 4 was 51%
to 100% tumor staining. At least 5% of cells had to stain for a
tumor core to be considered positive. Intensity was scored as 1
¼ no staining; 2 ¼ low intensity; 3 ¼ moderate; and 4 ¼ high
intensity. Scores for multiple cores from each patient were aver-
aged. For p53 mutation, p53 exons 4 to 9 were amplified by
using specific primers. Products from two polymerase chain
reactions were sequenced in both directions and were analyzed
by using Mutation Surveyor version 2.61 (Soft Genetics, State
College, PA) and by manual review.
For the immunohistologic evaluation of tumor infiltrating
lymphocytes (TILs), all tests were carried out on 5-lm forma-
lin-fixed, paraffin-embedded TMA sections. Sections were
baked in a hot-air oven at 65C overnight. Each section was
dewaxed using a series of xylene, graded alcohol, and buffer
immersion steps. Antigen retrieval was performed in a pre-
heated pressure cooker. Immunohistochemical staining was
performed on the DAKO Autostainer (DAKO, Carpinteria, CA)
using DAKO-labeled avidin-biotin-peroxidase method (LSABþ)
and 3,30-diaminobenzidine as the chromogen. Deparaffinized
sections were stained with five types of Mabs: CD4 1:250
(Abcam ab846), CD8 1:40 (Nova Castra VP-C320), FOXp3 1:200
(Abcam Ab20034), CD104 1:50 (Beta-4 integrin, eBioscience
439-9b), and CD68 1:100 (Dako M0814). Appropriate negative
(no primary antibody) and positive controls (tonsillar tissue
and various carcinomas) were stained in parallel with each set
of tumors studied. Digital photomicrographs were obtained at
20 magnification. The number of positively stained TILs for
CD4, CD8, FOXP3, and CD68 was assessed quantitatively by
two investigators blinded to patient outcome and HPV status.
Tissue cores were initially examined after CD104 (beta-4 integ-
rin) staining to confirm the presence and location of tumor
nodules in each core, and only TILs infiltrating tumor nodules
were counted (Fig. 1). This was because of the abundance of
lymphoid aggregates normally present in the peritumoral
stroma in oropharyngeal cancer patients that might not reflect
a tumor-related immune response. TILs in each tumor core on
the TMA were manually counted using a 20 objective lens.
Methods for counting were adapted from published methods
used to analyze T-cell infiltrates in follicular lymphoma and
head and neck TMAs.14,15 Three tumor cores and one normal
tissue core were provided from each patient represented on the
TMA. The mean count of replicate cores for each subject was
used for analysis.
Pretreatment peripheral blood was analyzed by routine
automated flow cytometry for T, B, and NK cells and subpopula-
tions of CD3-, CD4-, and CD8-positive T lymphocytes. Detailed
methods have been previously described.10,16 Determinations
were made using commercially available monoclonal antibody
reagents by an indirect immunofluorescent technique and were
performed in the clinical laboratories of the University of Michi-
gan Pathology Department. The results of correlations with
survival and HPV-16 status have been previously published.10
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Statistical Methods
Statistical analysis was carried out in two parts. First, all
subjects who had measured infiltrate levels (n ¼ 46) were ana-
lyzed for correlations with clinical outcomes, tumor, and patient
characteristics. Second, correlations between infiltrate levels
and peripheral blood lymphocyte levels (n ¼ 34) or HPV-16 sta-
tus (n ¼ 38) were performed on only those with both sets of
information.
Infiltrate levels were treated as continuous variables in all
analyses. Rank-based statistical methods were used to assess
univariate associations between infiltrate levels and covariates
of interest. Patient level averages for EGFR score were used in
this analysis. Patients were categorized as current, past (quit
>12 months prior), or never smokers. Spearman rank correla-
tion was used to assess the correlation with ordinal variables,
and the Wilcoxon rank sum test was used to test variables with
two groups.
Disease-specific survival (DSS) was defined as the time to
death from oropharyngeal cancer. Patients who were alive at
last follow-up or who died as a result of reasons other than
their cancer were censored. Cox proportional hazards models
were used to assess time-to-event outcomes. For each outcome,
three models were constructed: a model with infiltrate level
(treated as a continuous variable), a model with clinical varia-
bles, and a model with both clinical variables and infiltrate
level. Likelihood ratio tests were used to compare models, and
the maximum likelihood estimate for coefficients in a model
was used to test significance after controlling for other variables
in the model.
All statistical analyses were done in SAS version 9.2 (SAS
Institute, Carey, NC). Because of the relatively small sample
size, adjustments for multiple comparisons were not performed,
as these analyses were retrospective and exploratory in nature.
A two-tailed P value of .05 or less was considered statistically
significant.
RESULTS
The major finding in this study of immune cell infil-
trates in pretreatment biopsies from oropharyngeal
cancer patients was the lack of significant differences in
types of T-cell infiltrates among HPV-16–positive and
negative patients. The pattern of T-lymphocyte subset
infiltration did not differ by HPV-16 status in this group
of advanced oropharyngeal cancer patients entered in
this prospective, uniform treatment clinical trial.
Although the mean CD4/CD8 ratio of tumor-infiltrating
T lymphocytes tended to be lower in HPV-16–positive
patients and the sum of CD4 and CD8 cell infiltrate
counts tended to be higher, these differences were not
statistically different (Table I). Likewise, no differences
were noted for FoxP3 or CD68 infiltrate counts by HPV
status; however, the ratio of FoxP3 cells to CD8 cells
tended to be higher in HPV-negative patients (P ¼ .099)
primarily because of higher mean FoxP3 cell counts in
HPV-negative patients. This was in contrast to the sig-
nificant differences previously noted in the peripheral
blood T-lymphocyte subsets in these two groups of
patients where CD8 cell levels were higher and CD4 cell
levels were lower in HPV-16–positive patients.10
Fig. 1. Representative tissue microarray cores with immunohistochemical staining for CD4, CD8, FoxP3 cells, or beta-4 integrin (CD104).
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Our analysis confirmed that HPV-16 status and
EGFR expression were the most significant prognostic
factors for overall survival in this study (P ¼ .0455, haz-
ard ratio: 0.32, 95% confidence interval [CI]: 0.12-0.85;
and P ¼ .0083, hazard ratio: 1.89, 95% CI: 1.18-3.04,
respectively). When T-cell infiltrates were analyzed with
respect to overall survival, the infiltrate CD4/CD8 ratio
(P ¼ .0056) and sum of CD4 and CD8 mean infiltrate
counts were significant (P ¼ .0154) predictors of overall
survival and were still important after adjusting for
HPV status (P ¼ .034 and P ¼ .0298, respectively, Cox
regression). After controlling for EGFR, these T-cell infil-
trate measures remained significant (P ¼ .008 and P ¼
.04, respectively, Cox regression). Overall survival
tended to be better in patients with higher tumor infil-
trates of CD8 cells (P ¼ .0615), and the mean CD8
infiltrate count added prognostic significance after
adjusting for HPV status (P ¼ .0137, likelihood ratio
test). Mean infiltrate levels according to whether
patients survived or were dead are shown in Table II.
Likewise, higher FoxP3 infiltrate counts were also sig-
nificantly associated with better overall survival after
adjusting for HPV status (P ¼ .029, Cox regression).
DSS was significantly associated with EGFR
expression (P ¼ .015, hazard ratio: 1.95, 95% CI: 1.14-
3.35), HPV status (P ¼ .026, hazard ratio: 0.24, 95% CI:
0.07-0.82), peripheral blood CD4/CD8 ratio (P ¼ .047)
and smoking history (P ¼ .003). Of the various infiltrate
markers, only the infiltrate CD4/CD8 ratio, the FoxP3/
CD8 ratio, and sum of CD4 plus CD8 cell infiltrates
were significantly associated with DSS (P ¼ .0058, P ¼
.0457, and P ¼ .0244, respectively) (Fig. 2 and 3).
However, after adjusting for HPV-16 status, individual
levels of CD8 and FoxP3 infiltrates added significant
prognostic information (P ¼ .0236 and P ¼ .004, Likeli-
hood ratio test), and EGFR intensity remained an
important factor (Table III).
Smoking status was also a significant prognostic
factor for both overall survival (P ¼ .01) and DSS (P ¼
.003) and remained significant for DSS after controlling
for HPV-16 status (P ¼ .009). The sum of mean CD4 and
CD8 cell infiltrates was significantly higher in non-
smokers (P ¼ .047), and FoxP3 infiltrates also tended to
be higher in nonsmokers (P ¼ .081). After controlling for
TABLE I.
Mean (6 Standard Error of Mean) T-Cell Subset Infiltrates in
Human Papillomavirus-16–Positive and Negative Cancers.
HPV Negative (n ¼ 13) HPV Positive (n ¼ 25)
CD4 174 6 31 189 6 27
CD8 169 6 37 210 6 47
FoxP3 159 6 36 107 6 18
CD68 241 6 42 250 6 44
CD4 þ CD8 sum 345 6 62 413 6 66
CD4/CD8 ratio 4.16 6 2.78 1.56 6 0.35
FoxP3/CD8 ratio 1.27 6 0.32 0.74 6 0.12
HPV ¼ human papillomavirus.
TABLE II.
Mean (6 Standard Error of Mean) T-Cell Infiltrates
by Disease Status.
Alive Dead
CD4 203 6 27 152 6 21
CD8 253 6 50 130 6 22
FoxP3 149 6 27 98 6 19
CD68 267 6 43 209 6 36
CD4 þ CD8 sum 494 6 70 276 6 35
CD4/CD8 ratio 1.15 6 0.22 3.78 6 1.86
FoxP3/CD8 ratio 0.72 6 0.10 1.09 6 0.24
Fig. 2. Disease-specific survival was significantly better in patients
with low CD4/CD8 ratio in tumor infiltrates compared to patients
with higher (>median) ratio (P ¼ .0058).
Fig. 3. Disease-specific survival was significantly better in patients
with higher CD4 and CD8 T-cell tumor infiltrates compared to
patients with lower (<median) T-cell infiltrates (P ¼ .024). [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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smoking, the CD4/CD8 infiltrate ratio, the FoxP3/CD8
ratio, and the sum of CD4 and CD8 infiltrates were still
prognostically important for overall survival (P ¼ .046, P
¼ .0372, and P ¼ .029, respectively). After controlling for
smoking and EGFR intensity, the CD4/CD8 infiltrate ra-
tio was still prognostically important for overall (P ¼
.026) and DSS (P ¼ .030). For DSS, EGFR intensity,
HPV status, peripheral blood CD8 levels, and the CD4/
CD8 infiltrate ratio were significant prognostic factors
after controlling for smoking. For overall survival, after
controlling for both smoking and HPV status, both CD4/
CD8 ratio and infiltrate sum showed a trend for prog-
nostic significance (P ¼ .07 for each).
When clinical features were analyzed, there were
no significant differences in overall T-cell infiltrates with
respect to tumor stage, response to induction chemother-
apy, or overall tumor response after concurrent
chemoradiation. Overall survival and DSS did not differ
by tumor stage (P ¼ .9016) or T class (P ¼ .1727). How-
ever, overall and DSS differed significantly by N class (P
¼ .0237, P ¼ .0032 respectively). Mean CD8 infiltrates
and total CD4 and CD8 counts were higher in node-posi-
tive patients (P ¼ .011, Wilcoxon for both), yet CD8
infiltrates declined with increasing T class (P ¼ .003,
Spearman rho ¼ 0.424). Because CD8 infiltrates
increased with N stage and were associated with
improved survival, we analyzed N class with respect to
overall survival and DSS. We found that contrary to
what is typical for other tumor sites, increasing N class
was not a negative prognostic factor in this cohort of oro-
pharyngeal cancer patients. This was primarily due to
better DSS in patients with advanced (N2) neck disease.
This is likely related to patients with HPV-16–positive
cancers who often have small primary tumors and multi-
ple small lymph nodes or a single large cystic node.
Recurrence rates were highest in patients with N0 dis-
ease who had larger primary cancers. Interestingly, CD8
infiltrates were also significantly higher in association
with better patient Karnofsky performance status (P ¼
.003, Spearman rho ¼ 0.43), and the infiltrates of CD4
and FoxP3 cells also tended to be increased in those
patients (P ¼ .10, P ¼ .18, Spearman, respectively),
which resulted in the sum of T-cell infiltrates (CD4 plus
CD8) being significantly higher when performance sta-
tus was better (P ¼ .004, Spearman rho ¼ 0.45).
Individual T-cell subset infiltrates were not directly
associated with either EGFR expression or p53 mutation
status. T-cell subset levels in the peripheral blood were
available in 34 of the 46 patients with cancers analyzed
for T-cell tumor infiltrates. Type and degree of specific T-
cell subset infiltration was not related to peripheral
blood levels of the various subsets except for CD4 infil-
trates, which tended to be higher when peripheral blood
natural killer cell levels were low (P ¼ .0133, rho ¼
0.439). Levels of each of the infiltrate subsets except
for CD68 cells tended to be directly correlated with each
other (P < .0001) and with total T cells. In particular,
levels of FoxP3 cells correlated significantly and directly
with both CD4 (P ¼ .0364) and CD8 (P < .0001) infil-
trates. Levels of CD8 and FoxP3 cells were inversely
correlated with the CD4/CD8 ratio (P < .0001 and P ¼
.012, respectively).
DISCUSSION
This is the first study to correlate pretreatment pe-
ripheral blood T-lymphocyte levels with T-cell tumor
infiltrates in patients with advanced oropharyngeal can-
cer and to examine the association with HPV-16 status
and other known prognostic factors such as EGFR
expression, smoking status, tumor characteristics, and
performance status. A major finding was the lack of
association of T-cell infiltrates with HPV status or with
EGFR expression. This is particularly interesting since
our prior study of peripheral blood T-cell levels demon-
strated that increased CD8 cell levels were directly
associated with HPV-16 status, lower EGFR expression,
response to induction chemotherapy, and favorable prog-
nosis.10 This suggests that peripheral blood markers of
adaptive immunity are not surrogates for immune pa-
rameters in the primary tumor microenvironment.
Despite the lack of association with HPV status, the
lower tumor infiltrate CD4/CD8 ratio and higher mean
sum of CD4 and CD8 infiltrate were predictive of overall
survival and DSS, indicating that an immune response
in the local tumor microenvironment may be an impor-
tant factor in overall prognosis. Generally, TILs are
thought to represent a host immune response. It would
be expected that infiltrates would be beneficial.17 How-
ever, even in HPV-related cervical cancer, large
polyclonal infiltrates of T cells are seen that appear to be
functionally inactive.18 Animal model studies suggest
that multiple subtypes of CD4 and CD8 are necessary to
generate tumor reactive CD8 functional activity and
that TILs can be both immune reactive and immunosup-
pressive.19,20 Relative expansion of infiltrates of FoxP3
regulatory T cells (Treg) and cytotoxic T cells have been
described in head and neck cancer patients, and either
no association with outcome or improved locoregional tu-
mor control was found.15,21–23 In many other types of
cancer such as breast, colorectal, hepatocellular, gastric,
and pancreatic, high levels of tumor-infiltrating Treg
cells have been associated with poor outcome.24 These
were studies primarily of adenocarcinoma patients in
TABLE III.
P Values for the Association of Infiltrate Subsets With Disease-
Specific Survival by Cox Regression.
Univariate Adjusted for HPV-16 Status*
HPV-16† .0263 —
EGFR expression .0150 .0470
CD4/CD8 ratio .0058 .0554
CD4 þ CD8 sum .0244 .0197
FoxP3/CD8 ratio .0457 NS
CD8 .0848 .0236
FoxP3 .0824 .0040
*Likelihood ratio test.
†Log transformed.
HPV ¼ human papillomavirus; EGFR ¼ epidermal growth factor re-
ceptor; NS ¼ not significant.
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whom histology and immune reactivity differ from
patients with squamous carcinoma.
In our study, the associations of T-cell infiltrates
with survival remained significant after adjusting for
EGFR expression and HPV status. This important obser-
vation suggests that the local immune response and its
impact on outcome may be independent of other impor-
tant prognostic markers and not directly related to
peripheral blood measures of cellular immunity, which
previously were shown to differ by HPV status.10
Recently, gene signatures of adaptive immunity have
been shown to outperform HPV status in prognostica-
tion.21 Increased levels of CD3-positive tumor-
infiltrating T cells in general have been reported in oro-
pharyngeal cancer patients who were without regional
metastases that were related to HPV-16 status.12,22
Others have reported that higher levels of activated
CD4 and FoxP3 cells in tumor stroma are associated
with improved locoregional control and survival23 in a
patient cohort consisting of multiple sites of head and
neck cancer. CD4þ FoxP3þ regulatory T cells recovered
from the peripheral blood of head and neck cancer
patients have been associated with local immune sup-
pression mediated by IL-10 and TGF-beta.25 However,
higher levels of such suppressive cells in the blood were
found in patients with no evidence of disease after ther-
apy.25,26,27 Further, when analyzed in human tumor
sections, higher Treg cell levels were associated with
improved prognosis,23,28 which was consistent with our
findings. Levels of these cell populations may be less im-
portant than the balance of cells within tumor or
stroma. Improved survival has been reported for higher
ratios of CD8 to Treg cells in both tumor and stroma of
oral cancer.29 Our results are consistent with these
observations and indicate that this association is primar-
ily due to differences in levels of Treg cells rather than
CD8 cells. Also, understanding the function of such cells
in the local tumor environment and their influence on
the inflammatory response will be critical to determining
in what situations the local immune response and ratio
of effectors is beneficial or detrimental to outcome.
It is remarkable and encouraging that we found sig-
nificant associations of lymphocyte infiltrates with
outcome in this study, which utilized the small tissue
cores present on a tumor microarray created from pre-
treatment samples. Tumor-bearing tissue in the biopsies
was specifically selected by the pathologist in creating
the arrays; however, there was no effort to specifically
select any particular area of the tumor, leading to the
possibility of sampling errors for areas representative of
a local tumor immune response. Also, many of these
tumors had associated lymphoid components because of
the normal lymphoid tissue present in the tonsil and
tongue base sites, suggesting the possibility that some of
the infiltrates could represent resident normal lymphoid
aggregates. To minimize this potentially confounding
possibility, the tissue cores were also stained with Beta-
4 integrin (CD104) to specifically identify tumor within
the cores samples, and only T lymphocytes present in
the tumor nodules were counted to minimize this con-
founding variable.
This is the first analysis to look at response to
induction chemotherapy and local tumor immune pa-
rameters in patients with oropharyngeal cancers. We
previously found that higher systemic CD8 cell levels
were associated with tumor response to chemotherapy.
In this further analysis, we found that tumor response
was not associated with any of the T-lymphocyte infil-
trates. This was consistent with other reports of CD4þ
lymphocyte infiltrates measured in the stroma of a het-
erogeneous cohort of head and neck patients24 and
contrasts findings of higher tumor infiltrating CD8þ T
cells in metastatic lymph nodes from patients with
favorable outcomes.15 It was disappointing that tumor
response to chemotherapy was not associated with T-
lymphocyte infiltrates, as has been reported in breast
cancer.30
The consistent correlations of higher T-cell infil-
trates with favorable outcome are also reflected in the
association of higher CD8 infiltrates in patients with
lower T classifications and better performance status.
These patients would be expected to have a better out-
come. Infiltrate levels of CD4, CD8, and FoxP3 cells
were also associated with the important prognostic fac-
tor of smoking status, and a trend for improved survival
with higher infiltrates was present even after adjusting
for smoking habit. The potential effects of smoking on
tumor initiation, progression, epigenetic gene methyla-
tion and inflammation are probably some of the factors
influencing T-cell levels and outcome in oropharyngeal
cancer patients beyond simple HPV status. The relative
importance of these various factors related to the attrac-
tion and retention of immune cells to the tumor
microenvironment remains largely unknown. Our find-
ings extend those of others8,17,31 and suggest that
immunologic methods to increase immune reactive, cyto-
toxic CD8 cell levels in the peripheral blood or in the
tumor microenvironment may be beneficial in both
HPVþ and HPV cancer patients. Evidence from studies
in head and neck23,31,32 and other cancer types such as
breast,33 ovarian,34 or colon,35 support the conjecture
that there are differences in numbers and function of T
lymphocytes, and Treg cells in particular, in intratu-
moral versus peritumor stromal locations and that the
association of regulatory T cells with outcome differs by
tumor type.36 Thus, tumor-specific and site-specific stud-
ies in homogeneous populations of head and neck cancer
patients are necessary to better understand how periph-
eral blood levels and tumor infiltration by immune
reactive cells affect prognosis. It remains to be seen if
experimental vaccination schemes can modulate levels of
both regulatory and cytotoxic T cells in the tumor micro-
environment of patients with HPV-positive cancers.
CONCLUSION
Improved outcomes are associated with increased
TILs independent of HPV status and suggest the local
immune response in oropharyngeal cancer may be
related in part to factors such as tumor size, EGFR
expression, smoking history, performance status, or
innate immunity rather than HPV status. Assessment of
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TILs in tissue microarrays is difficult due to small core
sample size and variation in tumor representation in tis-
sue cores. Further study of larger numbers of patients
and infiltrates in whole tumor sections combined with
functional analysis of individual subsets may be neces-
sary to detect significant differences in local immunity
in HPV-16–related cancers. The lack of differences in
infiltrating T cells in patients with oropharyngeal cancer
regardless of HPV status suggest that immunotherapy
regimens that are effective in HPV-positive cancer
patients should also be explored in patients with HPV-
negative cancer.
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